Allergic Conjunctivitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Allergic Conjunctivitis – Pipeline Review, H2 2016’, provides an overview of the Allergic Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis

The report reviews pipeline therapeutics for Allergic Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Allergic Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Allergic Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accolade Pharmaceuticals, LLC

Aldeyra Therapeutics Inc

Allergan Plc

Clevexel Pharma SA

Griffin Discoveries BV

NicOx S.A.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Portola Pharmaceuticals, Inc.

Re-Pharm Limited

Sylentis S.A.U.

Xencor, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Allergic Conjunctivitis Overview 8

Therapeutics Development 9

Pipeline Products for Allergic Conjunctivitis - Overview 9

Allergic Conjunctivitis - Therapeutics under Development by Companies 10

Allergic Conjunctivitis - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Allergic Conjunctivitis - Products under Development by Companies 14

Allergic Conjunctivitis - Companies Involved in Therapeutics Development 15

Accolade Pharmaceuticals, LLC 15

Aldeyra Therapeutics Inc 16

Allergan Plc 17

Clevexel Pharma SA 18

Griffin Discoveries BV 19

NicOx S.A. 20

Ocular Therapeutix, Inc. 21

Ohr Pharmaceutical Inc. 22

Portola Pharmaceuticals, Inc. 23

Re-Pharm Limited 24

Sylentis S.A.U. 25

Xencor, Inc. 26

Allergic Conjunctivitis - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

ADX-102 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AGN-229666 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

cetirizine hydrochloride - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CVXL-0074 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

dexamethasone acetate SR - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Drugs for Allergic Conjunctivitis - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

GD-134 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

GD-136 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

PRT-2761 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

RP-0217 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

SYL-116011 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

XmAb-7195 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Zafi-2 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Allergic Conjunctivitis - Dormant Projects 59

Allergic Conjunctivitis - Discontinued Products 61

Allergic Conjunctivitis - Product Development Milestones 62

Featured News & Press Releases 62

Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day 62

Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis 62

Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis 64

Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis 64

Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 65

Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis 65

Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 66

Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial 67

Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis 67

Nov 24, 2014: Ora-CAC Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix’s OTX-DP in Allergic Conjunctivitis 68

Nov 12, 2014: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Allergic Conjunctivitis – Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 15

Allergic Conjunctivitis – Pipeline by Aldeyra Therapeutics Inc, H2 2016 16

Allergic Conjunctivitis – Pipeline by Allergan Plc, H2 2016 17

Allergic Conjunctivitis – Pipeline by Clevexel Pharma SA, H2 2016 18

Allergic Conjunctivitis – Pipeline by Griffin Discoveries BV, H2 2016 19

Allergic Conjunctivitis – Pipeline by NicOx S.A., H2 2016 20

Allergic Conjunctivitis – Pipeline by Ocular Therapeutix, Inc., H2 2016 21

Allergic Conjunctivitis – Pipeline by Ohr Pharmaceutical Inc., H2 2016 22

Allergic Conjunctivitis – Pipeline by Portola Pharmaceuticals, Inc., H2 2016 23

Allergic Conjunctivitis – Pipeline by Re-Pharm Limited, H2 2016 24

Allergic Conjunctivitis – Pipeline by Sylentis S.A.U., H2 2016 25

Allergic Conjunctivitis – Pipeline by Xencor, Inc., H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Allergic Conjunctivitis – Dormant Projects, H2 2016 59

Allergic Conjunctivitis – Dormant Projects (Contd..1), H2 2016 60

Allergic Conjunctivitis – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Allergic Conjunctivitis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports